Loading…
Back To Schedule
Wednesday, June 27 • 10:30am - 11:45am
#344: Biosimilar Interchangeability: A Global Perspective

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Tweet Share
Component Type: Forum
Level: Intermediate
CE: ACPE 1.25 Knowledge UAN: 0286-0000-18-653-L04-P; CME 1.25; IACET 1.25; RN 1.25

Biosimilars are the next big thing in cost-saving – that's been the promise for a while now, but why aren't we there yet? This session will discuss the successes and stumbles so far and gain insight on stimulating market access for interchangeable biosimilars.

Learning Objectives

Describe the various approaches regulators and payors in different countries have used to encourage the uptake of biosimilars; Compare the success of various education efforts for biosimilars; Identify how to plan strategies to address and take advantage of the specific market conditions for biosimilars in different countries; Analyze the incentives offered to sponsors to develop interchangeable biosimilars.

Chair

Nielsen Hobbs

Speaker

Regulatory Perspective
Steinar Madsen, MD

Panelist
Molly Burich, MPH

Panelist
Chad Pettit, MBA


Speakers
avatar for Nielsen Hobbs

Nielsen Hobbs

Executive Editor, US Policy and Regulatory, The Pink Sheet, United States
Nielsen Hobbs has more than 25 years of experience covering the pharmaceutical industry, and writes frequently about the intersection of business, regulation, science and politics. Before joining the “The Pink Sheet” he worked for Congressional Quarterly. Hobbs enjoys discussing... Read More →
SM

Steinar Madsen

Medical Director, Norwegian Medicines Agency
Dr. Steinar Madsen is medical director at the Norwegian Medicines Agency. He has been working with the safe and cost-effective use of generics and biosimilars for almost 20 years. He is a specialist in internal medicine and cardiology and works part time as a consultant in cardio... Read More →
avatar for Chad Pettit

Chad Pettit

Executive Director, Biosimilars Global Value Access & Policy, Amgen Inc.
Chad Pettit is the Executive Director Global Value Access and Policy for Amgen’s Biosimilars Business Unit with responsibility for market access launch strategy for the full Amgen portfolio of biosimilar products. Chad also serves as the Amgen board member on the Biosimilars Forum... Read More →

Wednesday June 27, 2018 10:30am - 11:45am EDT
Room 205AB Boston Convention and Exhibition Center 415 Summer Street, Boston, MA 02210 USA
  12: Value-Access, Forum